Show simple item record

Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease

dc.contributor.authorVrba, L.
dc.contributor.authorFutscher, B.W.
dc.contributor.authorOshiro, M.
dc.contributor.authorWatts, G.S.
dc.contributor.authorMenashi, E.
dc.contributor.authorHu, C.
dc.contributor.authorHammad, H.
dc.contributor.authorPennington, D.R.
dc.contributor.authorGolconda, U.
dc.contributor.authorGavini, H.
dc.contributor.authorRoe, D.J.
dc.contributor.authorShroff, R.T.
dc.contributor.authorNelson, M.A.
dc.date.accessioned2022-03-31T21:12:23Z
dc.date.available2022-03-31T21:12:23Z
dc.date.issued2022
dc.identifier.citationVrba, L., Futscher, B. W., Oshiro, M., Watts, G. S., Menashi, E., Hu, C., Hammad, H., Pennington, D. R., Golconda, U., Gavini, H., Roe, D. J., Shroff, R. T., & Nelson, M. A. (2022). Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease. Clinical Epigenetics.
dc.identifier.issn1868-7075
dc.identifier.pmid35193708
dc.identifier.doi10.1186/s13148-022-01246-2
dc.identifier.urihttp://hdl.handle.net/10150/663836
dc.description.abstractWe tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to distinguish malignant cases from benign disease with high sensitivity and specificity (AUC = 0.999). Furthermore, the biomarkers detected a consistent decline in tumor-derived cfDNA in samples from patients undergoing chemotherapy. The study indicates that our liquid biopsy assay could be useful for management of pancreatic cancer patients. © 2022, The Author(s).
dc.language.isoen
dc.publisherBioMed Central Ltd
dc.rightsCopyright © The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License.
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleLiquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease
dc.typeArticle
dc.typetext
dc.contributor.departmentUniversity of Arizona Cancer Center
dc.contributor.departmentDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Arizona
dc.contributor.departmentDivision of Hematology/Oncology, Department of Medicine, University of Arizona Cancer Center
dc.contributor.departmentDepartment of Pathology, College of Medicine, University of Arizona
dc.identifier.journalClinical Epigenetics
dc.description.noteOpen access journal
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.
dc.eprint.versionFinal published version
dc.source.journaltitleClinical Epigenetics
refterms.dateFOA2022-03-31T21:12:23Z


Files in this item

Thumbnail
Name:
s13148-022-01246-2.pdf
Size:
957.4Kb
Format:
PDF
Description:
Final Published Version
Download

This item appears in the following Collection(s)

Show simple item record

Copyright © The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License.
Except where otherwise noted, this item's license is described as Copyright © The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License.